Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0DHHKL)
| ADC Name |
AbA_S239C_LALA_IHH-PBD
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
AbA_S239C_LALA_IHH-PBD
Click to Show/Hide
|
|||||
| Organization |
Vor Biopharma Inec.
|
|||||
| Drug Status |
Investigative
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Receptor-type tyrosine-protein phosphatase C (PTPRC)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.04 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.042 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell killing assays: ADCs conjugated to AM1, AM4, or PBD
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.37 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 0.7142 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell line killing assays
|
||||
| In Vitro Model | Adult acute myeloid leukemia | SKNO-1 cells | CVCL_2196 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50) | 53 nM | Positive CD45,AbA expression (CD45,AbA +++/++) | ||
| Method Description |
In vitro cell killing assays: ADCs conjugated to AM1, AM4, or PBD
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||